Renaissance Technologies LLC Raises Stock Position in CEL-SCI Co. (NYSE:CVM)

Renaissance Technologies LLC lifted its position in CEL-SCI Co. (NYSE:CVM) by 29.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 173,800 shares of the company’s stock after buying an additional 40,000 shares during the period. Renaissance Technologies LLC owned approximately 0.32% of CEL-SCI worth $202,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CVM. Tidal Investments LLC purchased a new stake in shares of CEL-SCI in the 1st quarter valued at $27,000. Chilton Capital Management LLC lifted its stake in shares of CEL-SCI by 297.4% in the 1st quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock valued at $31,000 after purchasing an additional 12,200 shares during the period. Black Diamond Financial LLC lifted its stake in shares of CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after purchasing an additional 19,000 shares during the period. Cutter & CO Brokerage Inc. lifted its stake in shares of CEL-SCI by 29.4% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after purchasing an additional 24,634 shares during the period. Finally, Thoroughbred Financial Services LLC lifted its stake in shares of CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after purchasing an additional 80,001 shares during the period. Hedge funds and other institutional investors own 12.08% of the company’s stock.

CEL-SCI Stock Performance

NYSE:CVM opened at $1.01 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. The company has a fifty day moving average of $1.11 and a two-hundred day moving average of $1.29. The stock has a market capitalization of $64.43 million, a PE ratio of -1.74 and a beta of 0.65. CEL-SCI Co. has a fifty-two week low of $1.00 and a fifty-two week high of $3.23.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, research analysts forecast that CEL-SCI Co. will post -0.52 earnings per share for the current fiscal year.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.